Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives

Townsend, N.; Wilson, L.; Bhatnagar, P.; Wickramasinghe, K.; Rayner, M.; Nichols, M. Cardiovascular disease in Europe: epidemiological update 2016. Eur. Heart J., 2016, 37(42), 3232-3245.
[http://dx.doi.org/10.1093/eurheartj/ehw334] [PMID: 27523477]

Okur, M.E.; Karantas, I.D.; Okur, N.U.; Siafaka, P.I. Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations. Curr. Pharm. Des., 2017, 23(44), 6795-6814.
[http://dx.doi.org/10.2174/1381612823666170927123454] [PMID: 28969533]

Okur, M.E.; Karantas, I.D.; Siafaka, P.I. Diabetes Mellitus: A Review on Pathophysiology, Current Status of Oral Medications and Future Perspectives. Acta Pharm. Sci., 2017, 55(1), 61-82.
[http://dx.doi.org/10.23893/1307-2080.APS.0555]

Carbone, S.; Canada, J.M.; Billingsley, H.E.; Siddiqui, M.S.; Elagizi, A.; Lavie, C.J. Obesity paradox in cardiovascular disease: where do we stand? Vasc. Health Risk Manag., 2019, 15, 89-100.
[http://dx.doi.org/10.2147/VHRM.S168946] [PMID: 31118651]

Gidding, S.S.; Allen, N.B. Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem. J. Am. Heart Assoc., 2019, 8(11)e012924
[http://dx.doi.org/10.1161/JAHA.119.012924] [PMID: 31137996]

Libby, P.; Buring, J.E.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgözoğlu, L.; Lewis, E.F. Atherosclerosis. Nat. Rev. Dis. Primers, 2019, 5(1), 56.
[http://dx.doi.org/10.1038/s41572-019-0106-z] [PMID: 31420554]

Feingold, K.R.; Grunfeld, C. Lipids: a key player in the battle between the host and microorganisms. J. Lipid Res., 2012, 53(12), 2487-2489.
[http://dx.doi.org/10.1194/jlr.E033407] [PMID: 23075464]

Olivecrona, G. Role of lipoprotein lipase in lipid metabolism. Curr. Opin. Lipidol., 2016, 27(3), 233-241.
[http://dx.doi.org/10.1097/MOL.0000000000000297] [PMID: 27031275]

Kidambi, S.; Patel, S.B. Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review. Xenobiotica, 2008, 38(7-8), 1119-1139.
[http://dx.doi.org/10.1080/00498250802007930] [PMID: 18668442]

Dallinga-Thie, G.M.; Franssen, R.; Mooij, H.L.; Visser, M.E.; Hassing, H.C.; Peelman, F.; Kastelein, J.J.P.; Péterfy, M.; Nieuwdorp, M. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis, 2010, 211(1), 1-8.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.12.027] [PMID: 20117784]

Kindel, T.; Lee, D.M.; Tso, P. The mechanism of the formation and secretion of chylomicrons. Atheroscler. Suppl., 2010, 11(1), 11-16.
[http://dx.doi.org/10.1016/j.atherosclerosissup.2010.03.003] [PMID: 20493784]

Cox, R.; García-Palmieri, M. Cholesterol, Triglycerides, and Associated Lipoproteins.Clinical Methods: The History, Physical, and Laboratory Examinations; Walker, H.; Hall, W.; Hurst, J., Eds.; Butterworths: Boston, 1990, pp. 153-160.

Wengrofsky, P. Dyslipidemia and Its Role in the Pathogenesis of Atherosclerotic Cardiovascular Disease: Implications for Evaluation and Targets for Treatment of Dyslipidemia Based on Recent GuidelinesDyslipidemia; IntechOpen; , 2019.

García-Giustiniani, D.; Stein, R. Genetics of Dyslipidemia. Arq. Bras. Cardiol., 2016, 106(5), 434-438.
[PMID: 27305287]

Qi, L.; Ding, X.; Tang, W.; Li, Q.; Mao, D.; Wang, Y. Prevalence and Risk Factors Associated with Dyslipidemia in Chongqing, China. Int. J. Environ. Res. Public Health, 2015, 12(10), 13455-13465.
[http://dx.doi.org/10.3390/ijerph121013455] [PMID: 26516874]

Bayram, F.; Kocer, D.; Gundogan, K.; Kaya, A.; Demir, O.; Coskun, R.; Sabuncu, T.; Karaman, A.; Cesur, M.; Rizzo, M.; Toth, P.P.; Gedik, V. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J. Clin. Lipidol., 2014, 8(2), 206-216.
[http://dx.doi.org/10.1016/j.jacl.2013.12.011] [PMID: 24636181]

Kolovou, G.D.; Anagnostopoulou, K.K.; Cokkinos, D.V. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad. Med. J., 2005, 81(956), 358-366.
[http://dx.doi.org/10.1136/pgmj.2004.025601] [PMID: 15937200]

Leon, A.S.; Bronas, U.G. Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management. Am. J. Lifestyle Med., 2009, 3(4), 257-273.
[http://dx.doi.org/10.1177/1559827609334518]

Ruiz-Núñez, B.; Pruimboom, L.; Dijck-Brouwer, D.A.J.; Muskiet, F.A.J. Lifestyle and nutritional imbalances associated with Western diseases: causes and consequences of chronic systemic low-grade inflammation in an evolutionary context. J. Nutr. Biochem., 2013, 24(7), 1183-1201.
[http://dx.doi.org/10.1016/j.jnutbio.2013.02.009] [PMID: 23657158]

Becker, D.J.; Gordon, R.Y.; Morris, P.B.; Yorko, J.; Gordon, Y.J.; Li, M.; Iqbal, N. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin. Proc., 2008, 83(7), 758-764.
[http://dx.doi.org/10.4065/83.7.758] [PMID: 18613992]

Mohammadbeigi, A.; Moshiri, E.; Mohammadsalehi, N.; Ansari, H.; Ahmadi, A. Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients. World J. Mens Health, 2015, 33(3), 167-173.
[http://dx.doi.org/10.5534/wjmh.2015.33.3.167] [PMID: 26770936]

Kaur, J. A comprehensive review on metabolic syndrome. Cardiol. Res. Pract., 2014, 2014943162
[http://dx.doi.org/10.1155/2014/943162] [PMID: 24711954]

Rhee, E-J.; Kim, H.C.; Kim, J.H.; Lee, E.Y.; Kim, B.J.; Kim, E.M.; Song, Y.; Lim, J.H.; Kim, H.J.; Choi, S.; Moon, M.K.; Na, J.O.; Park, K-Y.; Oh, M.S.; Han, S.Y.; Noh, J.; Yi, K.H.; Lee, S-H.; Hong, S-C.; Jeong, I-K. 2018 Guidelines for the management of dyslipidemia. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.), 2019, 34(4), 723-771.
[http://dx.doi.org/10.3904/kjim.2019.188] [PMID: 31272142]

Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M-R.; Tokgozoglu, L.; Wiklund, O.; Mueller, C.; Drexel, H.; Aboyans, V.; Corsini, A.; Doehner, W.; Farnier, M.; Gigante, B.; Kayikcioglu, M.; Krstacic, G.; Lambrinou, E.; Lewis, B.S.; Masip, J.; Moulin, P.; Petersen, S.; Petronio, A.S.; Piepoli, M.F.; Pintó, X.; Räber, L.; Ray, K.K.; Reiner, Ž.; Riesen, W.F.; Roffi, M.; Schmid, J-P.; Shlyakhto, E.; Simpson, I.A.; Stroes, E.; Sudano, I.; Tselepis, A.D.; Viigimaa, M.; Vindis, C.; Vonbank, A.; Vrablik, M.; Vrsalovic, M.; Zamorano, J.L.; Collet, J-P.; Koskinas, K.C.; Casula, M.; Badimon, L.; John Chapman, M.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M-R.; Tokgozoglu, L.; Wiklund, O.; Windecker, S.; Aboyans, V.; Baigent, C.; Collet, J-P.; Dean, V.; Delgado, V.; Fitzsimons, D.; Gale, C.P.; Grobbee, D.; Halvorsen, S.; Hindricks, G.; Iung, B.; Jüni, P.; Katus, H.A.; Landmesser, U.; Leclercq, C.; Lettino, M.; Lewis, B.S.; Merkely, B.; Mueller, C.; Petersen, S.; Petronio, A.S.; Richter, D.J.; Roffi, M.; Shlyakhto, E.; Simpson, I.A.; Sousa-Uva, M.; Touyz, R.M.; Nibouche, D.; Zelveian, P.H.; Siostrzonek, P.; Najafov, R.; van de Borne, P.; Pojskic, B.; Postadzhiyan, A.; Kypris, L.; Špinar, J.; Larsen, M.L.; Eldin, H.S.; Viigimaa, M.; Strandberg, T.E.; Ferrières, J.; Agladze, R.; Laufs, U.; Rallidis, L.; Bajnok, L.; Gudjónsson, T.; Maher, V.; Henkin, Y.; Gulizia, M.M.; Mussagaliyeva, A.; Bajraktari, G.; Kerimkulova, A.; Latkovskis, G.; Hamoui, O.; Slapikas, R.; Visser, L.; Dingli, P.; Ivanov, V.; Boskovic, A.; Nazzi, M.; Visseren, F.; Mitevska, I.; Retterstøl, K.; Jankowski, P.; Fontes-Carvalho, R.; Gaita, D.; Ezhov, M.; Foscoli, M.; Giga, V.; Pella, D.; Fras, Z.; de Isla, L.P.; Hagström, E.; Lehmann, R.; Abid, L.; Ozdogan, O.; Mitchenko, O.; Patel, R.S. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020, 41(1), 111-188.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]

Gustafsson, M.; Flood, C.; Jirholt, P.; Borén, J. Retention of atherogenic lipoproteins in atherogenesis. Cell. Mol. Life Sci., 2004, 61(1), 4-9.
[http://dx.doi.org/10.1007/s00018-003-3262-x] [PMID: 14704849]

Tsimikas, S.; Karwatowska-Prokopczuk, E.; Gouni-Berthold, I.; Tardif, J-C.; Baum, S.J.; Steinhagen-Thiessen, E.; Shapiro, M.D.; Stroes, E.S.; Moriarty, P.M.; Nordestgaard, B.G.; Xia, S.; Guerriero, J.; Viney, N.J.; O’Dea, L.; Witztum, J.L. AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N. Engl. J. Med., 2020, 382(3), 244-255.
[http://dx.doi.org/10.1056/NEJMoa1905239] [PMID: 31893580]

Stulnig, T.M.; Morozzi, C.; Reindl-Schwaighofer, R.; Stefanutti, C. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice. Curr. Atheroscler. Rep., 2019, 21(10), 37.
[http://dx.doi.org/10.1007/s11883-019-0803-9] [PMID: 31350625]

Lippi, G.; Guidi, G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit. Rev. Clin. Lab. Sci., 2003, 40(1), 1-42.
[http://dx.doi.org/10.1080/713609328] [PMID: 12627747]

O’Donoghue, M.L.; Fazio, S.; Giugliano, R.P.; Stroes, E.S.G.; Kanevsky, E.; Gouni-Berthold, I.; Im, K.; Lira Pineda, A.; Wasserman, S.M.; Češka, R.; Ezhov, M.V.; Jukema, J.W.; Jensen, H.K.; Tokgözoğlu, S.L.; Mach, F.; Huber, K.; Sever, P.S.; Keech, A.C.; Pedersen, T.R.; Sabatine, M.S. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139(12), 1483-1492.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037184] [PMID: 30586750]

Tsimikas, S.; Viney, N.J.; Hughes, S.G.; Singleton, W.; Graham, M.J.; Baker, B.F.; Burkey, J.L.; Yang, Q.; Marcovina, S.M.; Geary, R.S.; Crooke, R.M.; Witztum, J.L. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet, 2015, 386(10002), 1472-1483.
[http://dx.doi.org/10.1016/S0140-6736(15)61252-1] [PMID: 26210642]

Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; Watts, G.F.; Borén, J.; Fazio, S.; Horton, J.D.; Masana, L.; Nicholls, S.J.; Nordestgaard, B.G.; van de Sluis, B.; Taskinen, M-R.; Tokgözoglu, L.; Landmesser, U.; Laufs, U.; Wiklund, O.; Stock, J.K.; Chapman, M.J.; Catapano, A.L. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J., 2017, 38(32), 2459-2472.
[http://dx.doi.org/10.1093/eurheartj/ehx144] [PMID: 28444290]

Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and atherosclerosis. Circulation, 2002, 105(9), 1135-1143.
[http://dx.doi.org/10.1161/hc0902.104353] [PMID: 11877368]

Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2012, 32(9), 2045-2051.
[http://dx.doi.org/10.1161/ATVBAHA.108.179705] [PMID: 22895665]

Moore, K.J.; Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell, 2011, 145(3), 341-355.
[http://dx.doi.org/10.1016/j.cell.2011.04.005] [PMID: 21529710]

Moore, K.J.; Sheedy, F.J.; Fisher, E.A. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol., 2013, 13(10), 709-721.
[http://dx.doi.org/10.1038/nri3520] [PMID: 23995626]

Helkin, A.; Stein, J.J.; Lin, S.; Siddiqui, S.; Maier, K.G.; Gahtan, V. Dyslipidemia Part 1--Review of Lipid Metabolism and Vascular Cell Physiology. Vasc. Endovascular Surg., 2016, 50(2), 107-118.
[http://dx.doi.org/10.1177/1538574416628654] [PMID: 26983667]

Zak, A.; Zeman, M.; Slaby, A.; Vecka, M. Xanthomas: clinical and pathophysiological relations. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2014, 158(2), 181-188.
[http://dx.doi.org/10.5507/bp.2014.016] [PMID: 24781043]

Ladizinski, B.; Lee, K.C. Eruptive xanthomas in a patient with severe hypertriglyceridemia and type 2 diabetes. CMAJ, 2013, 185(18), 1600-1600.
[http://dx.doi.org/10.1503/cmaj.130148] [PMID: 23754108]

de Pretis, N.; Amodio, A.; Frulloni, L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United European Gastroenterol. J., 2018, 6(5), 649-655.
[http://dx.doi.org/10.1177/2050640618755002] [PMID: 30083325]

Wong, S.; Shields, R.; Silva, R.A. Lipemia Retinalis in a Woman With Hypertriglyceridemia. JAMA Ophthalmol., 2019, 137(11)e186224
[http://dx.doi.org/10.1001/jamaophthalmol.2018.6224] [PMID: 31725839]

Tremblay, K.; Méthot, J.; Brisson, D.; Gaudet, D. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J. Clin. Lipidol., 2011, 5(1), 37-44.
[http://dx.doi.org/10.1016/j.jacl.2010.11.004] [PMID: 21262505]

Inokuchi, R.; Matsumoto, A.; Azihara, R.; Sato, H.; Kumada, Y.; Yokoyama, H.; Okada, M.; Ishida, T.; Nakamura, K.; Nakajima, S.; Yahagi, N.; Shinohara, K. Hypertriglyceridemia as a possible cause of coma: a case report. J. Med. Case Reports, 2012, 6(1), 412.
[http://dx.doi.org/10.1186/1752-1947-6-412] [PMID: 23198781]

Toor, A.; Toor, A.; Khalighi, K.; Krishnamurthy, M. Triglyceride Levels Greater Than 10,000 mg/dL in a 49-Year-Old Female without Evidence of Pancreatitis. Case Rep. Endocrinol., 2019, 20196273196
[http://dx.doi.org/10.1155/2019/6273196] [PMID: 31240137]

Avasia, A.R.; Rodziewicz, N.; Bhushan, S.; Singh, N. Milky Serum in Hypertriglyceridemia: Clinical Image. Arch. Case Reports Clin. Med., 2015, 01(01), 104.

Taddei, C.; Jackson, R.; Zhou, B.; Bixby, H.; Danaei, G.; Di Cesare, M.; Kuulasmaa, K.; Hajifathalian, K.; Bentham, J.; Bennett, J.E.; Aekplakorn, W.; Cifkova, R.; Dallongeville, J.; DeBacquer, D.; Giampaoli, S.; Gudnason, V.; Khang, Y-H.; Laatikainen, T.; Mann, J.; Marques-Vidal, P.; Mensah, G.A.; Müller-Nurasyid, M.; Ninomiya, T.; Petkeviciene, J.; Rodríguez-Artalejo, F.; Servais, J.; Söderberg, S.; Stavreski, B.; Wilsgaard, T.; Zdrojewski, T.; Zhao, D.; Stevens, G.A.; Savin, S.; Cowan, M.J.; Riley, L.M.; Ezzati, M.; Adams, R.J.; Aekplakorn, W.; Ahrens, W.; Amouyel, P.; Amuzu, A.; Anderssen, S.A.; Ariansen, I.; Arveiler, D.; Aspelund, T.; Auvinen, J.; Avdicová, M.; Banach, M.; Bandosz, P.; Banegas, J.R.; Barbagallo, C.M.; Bata, I.; Baur, L.A.; Beaglehole, R.; Bennett, J.E.; Bernotiene, G.; Bi, Y.; Bienek, A.; Björkelund, C.; Bo, S.; Boehm, B.O.; Bonaccio, M.; Bongard, V.; Borchini, R.; Borghs, H.; Breckenkamp, J.; Brenner, H.; Bruno, G.; Busch, M.A.; Cabrera de León, A.; Capuano, V.; Casanueva, F.F.; Casas, J-P.; Caserta, C.A.; Censi, L.; Chen, F.; Chen, S.; Chirlaque, M-D.; Cho, B.; Cho, Y.; Chudek, J.; Cifkova, R.; Claessens, F.; Clarke, J.; Clays, E.; Cooper, C.; Costanzo, S.; Cottel, D.; Cowell, C.; Crujeiras, A.B.; Cui, L.; D’Arrigo, G.; Dallongeville, J.; Dauchet, L.; De Backer, G.; De Bacquer, D.; de Gaetano, G.; De Henauw, S.; De Smedt, D.; Dennison, E.; Deschamps, V.; DiCastelnuovo, A.; Dobson, A.J.; Donfrancesco, C.; Döring, A.; Drygas, W.; Du, Y.; Dziankowska-Zaborszczyk, E.; Eggertsen, R.; Ekelund, U.; Elosua, R.; Eriksson, J.G.; Evans, A.; Faeh, D.; Felix-Redondo, F.J.; Fernández-Bergés, D.; Ferrari, M.; Ferrieres, J.; Finn, J.D.; Forslund, A-S.; Forsner, M.; Frontera, G.; Fujita, Y.; Gaciong, Z.; Galvano, F.; Gao, J.; Garcia-de-la-Hera, M.; Garnett, S.P.; Gaspoz, J-M.; Gasull, M.; Gates, L.; Giampaoli, S.; Gianfagna, F.; Gill, T.K.; Giovannelli, J.; Goltzman, D. NCD Risk Factor Collaboration (NCD-RisC). National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. Int. J. Epidemiol., 2020, 49(1), 173-192.
[http://dx.doi.org/10.1093/ije/dyz099] [PMID: 31321439]

Oğuz, A.; Güleç, S.; Temizhan, A.; Altuntaş, Y.; Karşıdağ, K.; Akalın, A.A.; Tümerdem Çalık, B.; İmeryüz, N. The Frequency of Dyslipidemia in Adults in Turkey. J. Am. Coll. Cardiol., 2013, 62(18), C6.
[http://dx.doi.org/10.1016/j.jacc.2013.08.025]

Kayıkçıoğlu, M. Systematic Review and Meta-Analysis of Epidemiological Studies for Cardiovascular Risk Factors Conducted in Turkey: Prevelance of Dislipidemias and Lipid Data. Turk Kardiyol. Dern. Arsivi-Archives Turkish Soc. Cardiol., 2018, 46(7), 556-574.
[http://dx.doi.org/10.5543/tkda.2018.23450]

Elisaf, M.; Tzouvelekis, E.; Nikas, N. Greek EURIKA Investigators. Primary prevention of cardiovascular disease in Greece: Greek results of the EURIKA study. Hellenic J. Cardiol., 2014, 55(3), 217-226.
[PMID: 24862614]

Sbarouni, E.; Voudris, V.; Georgiadou, P.; Hamilos, M.; Steg, P.G.; Fox, K.M.; Greenlaw, N.; Ferrari, R.; Vardas, P.E. Clinical presentation and management of stable coronary artery disease: insights from the international prospective CLARIFY registry - results from the Greek national cohort. Hellenic J. Cardiol., 2014, 55(6), 442-447.
[PMID: 25432195]

Andrikopoulos, G.; Tzeis, S.; Mantas, I.; Olympios, C.; Kitsiou, A.; Kartalis, A.; Kranidis, A.; Tsaknakis, T.; Richter, D.; Pras, A.; Pipilis, A.; Lampropoulos, S.; Oikonomou, K.; Gotsis, A.; Anastasiou-Nana, M.; Triposkiadis, F.; Goudevenos, J.; Theodorakis, G.; Vardas, P. Epidemiological characteristics and in-hospital management of acute coronary syndrome patients in Greece: results from the TARGET study. Hellenic J. Cardiol., 2012, 53(1), 33-40.
[PMID: 22275741]

Stone, N.J.; Robinson, J.G.; Lichtenstein, A.H.; Bairey Merz, C.N.; Blum, C.B.; Eckel, R.H.; Goldberg, A.C.; Gordon, D.; Levy, D.; Lloyd-Jones, D.M.; McBride, P.; Schwartz, J.S.; Shero, S.T.; Smith, S.C., Jr; Watson, K.; Wilson, P.W.F.; Eddleman, K.M.; Jarrett, N.M.; LaBresh, K.; Nevo, L.; Wnek, J.; Anderson, J.L.; Halperin, J.L.; Albert, N.M.; Bozkurt, B.; Brindis, R.G.; Curtis, L.H.; DeMets, D.; Hochman, J.S.; Kovacs, R.J.; Ohman, E.M.; Pressler, S.J.; Sellke, F.W.; Shen, W.K.; Smith, S.C., Jr; Tomaselli, G.F. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129(25)(Suppl. 2), S1-S45.
[http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a] [PMID: 24222016]

Jellinger, P.S.; Handelsman, Y.; Rosenblit, P.D.; Bloomgarden, Z.T.; Fonseca, V.A.; Garber, A.J.; Grunberger, G.; Guerin, C.K.; Bell, D.S.H.; Mechanick, J.I.; Pessah-Pollack, R.; Wyne, K.; Smith, D.; Brinton, E.A.; Fazio, S.; Davidson, M. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr. Pract., 2017, 23(Suppl. 2), 1-87.
[http://dx.doi.org/10.4158/EP171764.APPGL] [PMID: 28437620]

Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; Sever, P.S.; Pedersen, T.R. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med., 2017, 376(18), 1713-1722.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]

Cannon, C.P.; Blazing, M.A.; Giugliano, R.P.; McCagg, A.; White, J.A.; Theroux, P.; Darius, H.; Lewis, B.S.; Ophuis, T.O.; Jukema, J.W.; De Ferrari, G.M.; Ruzyllo, W.; De Lucca, P.; Im, K.; Bohula, E.A.; Reist, C.; Wiviott, S.D.; Tershakovec, A.M.; Musliner, T.A.; Braunwald, E.; Califf, R.M. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med., 2015, 372(25), 2387-2397.
[http://dx.doi.org/10.1056/NEJMoa1410489] [PMID: 26039521]

Schwartz, G.G.; Steg, P.G.; Szarek, M.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; Jukema, J.W.; Lecorps, G.; Mahaffey, K.W.; Moryusef, A.; Pordy, R.; Quintero, K.; Roe, M.T.; Sasiela, W.J.; Tamby, J-F.; Tricoci, P.; White, H.D.; Zeiher, A.M. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N. Engl. J. Med., 2018, 379(22), 2097-2107.
[http://dx.doi.org/10.1056/NEJMoa1801174] [PMID: 30403574]

Garg, N.; Muduli, S.K.; Kapoor, A.; Tewari, S.; Kumar, S.; Khanna, R.; Goel, P.K. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J., 2017, 69(4), 458-463.
[http://dx.doi.org/10.1016/j.ihj.2017.01.015] [PMID: 28822511]

Cartier, L-J.; Collins, C.; Lagacé, M.; Douville, P. Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. Clin. Biochem., 2018, 52, 61-66.
[http://dx.doi.org/10.1016/j.clinbiochem.2017.11.007] [PMID: 29129625]

Catapano, A.L.; Graham, I.; De Backer, G.; Wiklund, O.; Chapman, M.J.; Drexel, H.; Hoes, A.W.; Jennings, C.S.; Landmesser, U.; Pedersen, T.R.; Reiner, Ž.; Riccardi, G.; Taskinen, M-R.; Tokgozoglu, L.; Verschuren, W.M.M.; Vlachopoulos, C.; Wood, D.A.; Zamorano, J.L.; Cooney, M.T. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J., 2016, 37(39), 2999-3058.
[http://dx.doi.org/10.1093/eurheartj/ehw272] [PMID: 27567407]

Hennekens, C.H.; Lopez-Sendon, J. Overview of the prevention of cardiovascular disease events in those with established disease (secondary prevention) or at high risk Available at: https://www.uptodate.com/contents/overview-of-the-prevention-of-cardiovascular-disease-events-in-those-with-established-disease-secondary-prevention-or-at-high-risk

Jin, J. Lipid Disorders: Screening and Treatment. JAMA, 2016, 316(19), 2056.
[http://dx.doi.org/10.1001/jama.2016.16650] [PMID: 27838718]

Arsenault, B.J.; Rana, J.S.; Stroes, E.S.G.; Després, J-P.; Shah, P.K.; Kastelein, J.J.P.; Wareham, N.J.; Boekholdt, S.M.; Khaw, K-T. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J. Am. Coll. Cardiol., 2009, 55(1), 35-41.
[http://dx.doi.org/10.1016/j.jacc.2009.07.057] [PMID: 20117361]

Thanassoulis, G. Screening for High Lipoprotein(a). Circulation, 2019, 139(12), 1493-1496.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.038989] [PMID: 30883219]

Weiss, M.C.; Berger, J.S.; Gianos, E.; Fisher, E.; Schwartzbard, A.; Underberg, J.; Weintraub, H. Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. J. Clin. Lipidol., 2017, 11(5), 1177-1180.
[http://dx.doi.org/10.1016/j.jacl.2017.07.005] [PMID: 28801030]

Pollin, T.I.; Quartuccio, M. What We Know About Diet, Genes, and Dyslipidemia: Is There Potential for Translation? Curr. Nutr. Rep., 2013, 2(4), 236-242.
[http://dx.doi.org/10.1007/s13668-013-0065-z] [PMID: 24524012]

Drouin-Chartier, J-P.; Tremblay, A.J.; Lépine, M-C.; Lemelin, V.; Lamarche, B.; Couture, P. Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial. Am. J. Clin. Nutr., 2018, 107(1), 26-34.
[http://dx.doi.org/10.1093/ajcn/nqx013] [PMID: 29381796]

Riccardi, G.; Vaccaro, O.; Costabile, G.; Rivellese, A.A. How Well Can We Control Dyslipidemias Through Lifestyle Modifications? Curr. Cardiol. Rep., 2016, 18(7), 66.
[http://dx.doi.org/10.1007/s11886-016-0744-7] [PMID: 27216846]

Handelsman, Y.; Lepor, N.E. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J. Am. Heart Assoc., 2018, 7(13)e008953
[http://dx.doi.org/10.1161/JAHA.118.008953] [PMID: 29934421]

Tai, M-H.; Shepherd, J.; Bailey, H.; Williams, N.; Hatz, M.; Campos Tapias, I.; Catterick, D.; Worth, G. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom. Curr. Med. Res. Opin., 2019, 35(5), 829-835.
[http://dx.doi.org/10.1080/03007995.2018.1532885] [PMID: 30289004]

EMA. EMA report, https://www.ema.europa.eu/en/

Agrawal, N.; Freitas Corradi, P.; Gumaste, N.; Goldberg, I.J. Triglyceride Treatment in the Age of Cholesterol Reduction. Prog. Cardiovasc. Dis., 2016, 59(2), 107-118.
[http://dx.doi.org/10.1016/j.pcad.2016.08.003] [PMID: 27544319]

Ansell, B.J. Rationale for Combination Therapy with Statin Drugs in the Treatment of Dyslipidemia. Curr. Atheroscler. Rep., 2005, 7(1), 29-33.
[http://dx.doi.org/10.1007/s11883-005-0072-7]

Garg, A. Treatment of Diabetic Dyslipidemia.American Journal of Cardiology; Elsevier Inc., 1998, Vol. 81, pp. 47B-51B.

Ginsberg, H.N. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab., 2006, 91(2), 383-392.
[http://dx.doi.org/10.1210/jc.2005-2084] [PMID: 16291700]

Bonfim, M.R.; Oliveira, A.S.B.; do Amaral, S.L.; Monteiro, H.L. Treatment of dyslipidemia with statins and physical exercises: recent findings of skeletal muscle responses. Arq. Bras. Cardiol., 2015, 104(4), 324-331.
[http://dx.doi.org/10.5935/abc.20150005] [PMID: 25993596]

Fazio, S. The Role of Statin Therapy in Primary Hyperlipidemia and Mixed Dyslipidemia. US Endocrinol., 2011, 7(1), 23-29.
[http://dx.doi.org/10.17925/USE.2011.07.01.23]

Gau, G.T.; Wright, R.S. Pathophysiology, diagnosis, and management of dyslipidemia. Curr. Probl. Cardiol., 2006, 31(7), 445-486.
[http://dx.doi.org/10.1016/j.cpcardiol.2006.03.001] [PMID: 16824902]

Clark, L.T. Treating dyslipidemia with statins: the risk-benefit profile. Am. Heart J., 2003, 145(3), 387-396.
[http://dx.doi.org/10.1067/mhj.2003.70] [PMID: 12660659]

Stancu, C.; Sima, A. Statins: mechanism of action and effects. J. Cell. Mol. Med., 2001, 5(4), 378-387.
[http://dx.doi.org/10.1111/j.1582-4934.2001.tb00172.x] [PMID: 12067471]

Korani, S.; Bahrami, S.; Korani, M.; Banach, M.; Johnston, T.P.; Sahebkar, A. Parenteral systems for statin delivery: a review. Lipids Health Dis., 2019, 18(1), 193.
[http://dx.doi.org/10.1186/s12944-019-1139-8] [PMID: 31690335]

Zidan, A.S.; Hosny, K.M.; Ahmed, O.A.A.; Fahmy, U.A. Assessment of simvastatin niosomes for pediatric transdermal drug delivery. Drug Deliv., 2016, 23(5), 1536-1549.
[PMID: 25386740]

Tatham, L.M.; Liptrott, N.J.; Rannard, S.P.; Owen, A. Long-Acting Injectable Statins-Is It Time for a Paradigm Shift? Molecules, 2019, 24(15), 2685.
[http://dx.doi.org/10.3390/molecules24152685] [PMID: 31344834]

Shidhaye, S.S.; Thakkar, P.V.; Dand, N.M.; Kadam, V.J. Buccal drug delivery of pravastatin sodium. AAPS PharmSciTech, 2010, 11(1), 416-424.
[http://dx.doi.org/10.1208/s12249-010-9381-4] [PMID: 20300898]

Phan, B.A.; Dayspring, T.D.; Toth, P.P. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag., 2012, 8, 415-427.
[http://dx.doi.org/10.2147/VHRM.S33664] [PMID: 22910633]

Din, F. ud; Zeb, A.; Shah, K. U.; Zia-ur-Rehman. Development, in-Vitro and in-Vivo Evaluation of Ezetimibe-Loaded Solid Lipid Nanoparticles and Their Comparison with Marketed Product. J. Drug Deliv. Sci. Technol., 2019, 51, 583-590.
[http://dx.doi.org/10.1016/j.jddst.2019.02.026]

Shukr, M.H.; Ismail, S.; Ahmed, S.M. Development and Optimization of Ezetimibe Nanoparticles with Improved Antihyperlipidemic Activity. J. Drug Deliv. Sci. Technol., 2019, 49, 383-395.
[http://dx.doi.org/10.1016/j.jddst.2018.12.001]

Everett, B.M.; Smith, R.J.; Hiatt, W.R. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N. Engl. J. Med., 2015, 373(17), 1588-1591.
[http://dx.doi.org/10.1056/NEJMp1508120] [PMID: 26444323]

Page, M.M.; Watts, G.F. PCSK9 inhibitors - mechanisms of action. Aust. Prescr., 2016, 39(5), 164-167.
[http://dx.doi.org/10.18773/austprescr.2016.060] [PMID: 27789927]

Chaudhary, R.; Garg, J.; Shah, N.; Sumner, A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J. Cardiol., 2017, 9(2), 76-91.
[http://dx.doi.org/10.4330/wjc.v9.i2.76] [PMID: 28289523]

Porez, G.; Prawitt, J.; Gross, B.; Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid Res., 2012, 53(9), 1723-1737.
[http://dx.doi.org/10.1194/jlr.R024794] [PMID: 22550135]

William, I., Jr Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South. Med. J., 2006, 99(3), 257-273.
[http://dx.doi.org/10.1097/01.smj.0000208120.73327.db] [PMID: 16553100]

Staels, B.; Handelsman, Y.; Fonseca, V. Bile acid sequestrants for lipid and glucose control. Curr. Diab. Rep., 2010, 10(1), 70-77.
[http://dx.doi.org/10.1007/s11892-009-0087-5] [PMID: 20425070]

Pavlović, N.; Goločorbin-Kon, S.; Ðanić, M.; Stanimirov, B.; Al-Salami, H.; Stankov, K.; Mikov, M. Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. Front. Pharmacol., 2018, 9, 1283.
[http://dx.doi.org/10.3389/fphar.2018.01283] [PMID: 30467479]

Sahebkar, A.; Simental-Mendía, L.E.; Watts, G.F.; Serban, M-C.; Banach, M. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med., 2017, 15(1), 22.
[http://dx.doi.org/10.1186/s12916-017-0787-7] [PMID: 28153024]

Ling, H.; Luoma, J.T.; Hilleman, D. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiol. Res., 2013, 4(2), 47-55.
[http://dx.doi.org/10.4021/cr270w] [PMID: 28352420]

Fernández-Martínez, E.; Lira-Islas, I.G.; Cariño-Cortés, R.; Soria-Jasso, L.E.; Pérez-Hernández, E.; Pérez-Hernández, N. Dietary chia seeds (Salvia hispanica) improve acute dyslipidemia and steatohepatitis in rats. J. Food Biochem., 2019, 43(9)e12986
[http://dx.doi.org/10.1111/jfbc.12986] [PMID: 31489674]

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103).

Chen, Q.; Liu, M.; Zhang, P.; Fan, S.; Huang, J.; Yu, S.; Zhang, C.; Li, H. Fucoidan and galactooligosaccharides ameliorate high-fat diet-induced dyslipidemia in rats by modulating the gut microbiota and bile acid metabolism. Nutrition, 2019, 65, 50-59.
[http://dx.doi.org/10.1016/j.nut.2019.03.001] [PMID: 31029922]

Chávez-Talavera, O.; Tailleux, A.; Lefebvre, P.; Staels, B. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2017, 152(7), 1679-1694.e3.
[http://dx.doi.org/10.1053/j.gastro.2017.01.055] [PMID: 28214524]

Fiorucci, S.; Cipriani, S.; Baldelli, F.; Mencarelli, A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res., 2010, 49(2), 171-185.
[http://dx.doi.org/10.1016/j.plipres.2009.11.001] [PMID: 19932133]

Aldridge, M.A.; Ito, M.K. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother., 2001, 35(7-8), 898-907.
[http://dx.doi.org/10.1345/aph.10263] [PMID: 11485143]

Acharya, P.; Nanjaiah, L.; Singh, S.A.; Talahalli, R.R. Hyperglycemia Exacerbates Dyslipidemia-Induced Changes in Uptake, Synthesis, and Transporters of Bile Acids in Rats: Assessment of Restorative Potentials of ALA and EPA + DHA. J. Funct. Foods, 2019, 54(January), 329-336.
[http://dx.doi.org/10.1016/j.jff.2019.01.038]

Huijgen, R.; Abbink, E.J.; Bruckert, E.; Stalenhoef, A.F.H.; Imholz, B.P.M.; Durrington, P.N.; Trip, M.D.; Eriksson, M.; Visseren, F.L.J.; Schaefer, J.R.; Kastelein, J.J.P. Triple Study Group. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin. Ther., 2010, 32(4), 615-625.
[http://dx.doi.org/10.1016/j.clinthera.2010.04.014] [PMID: 20435231]

Ishibashi, S.; Arai, H.; Yokote, K.; Araki, E.; Suganami, H.; Yamashita, S. K-877 Study Group. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J. Clin. Lipidol., 2018, 12(1), 173-184.
[http://dx.doi.org/10.1016/j.jacl.2017.10.006] [PMID: 29203092]

Jones, P.H. Fibrates. In:Clinical Lipidology; Elsevier, 2009, pp. 315-325.
[http://dx.doi.org/10.1016/B978-141605469-6.50030-5]

Jackevicius, C.A.; Tu, J.V.; Ross, J.S.; Ko, D.T.; Carreon, D.; Krumholz, H.M. Use of fibrates in the United States and Canada. JAMA, 2011, 305(12), 1217-1224.
[http://dx.doi.org/10.1001/jama.2011.353] [PMID: 21427374]

Nordmann, A.J.; Ferreira-González, I.; Kasenda, B.; Saccilotto, R.; Bassler, D.; Bhatnagar, N.; Briel, M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst. Rev., 2012, 3(3)CD009753
[http://dx.doi.org/10.1002/14651858.CD009753] [PMID: 25267898]

Zimetbaum, P.; Frishman, W.H.; Kahn, S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J. Clin. Pharmacol., 1991, 31(1), 25-37.
[http://dx.doi.org/10.1002/j.1552-4604.1991.tb01883.x] [PMID: 2045526]

Cavallero, E.; Piolot, A.; Jacotot, B. Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects. Diabete Metab., 1995, 21(2), 118-120.
[PMID: 7621971]

Mosca, L.; Banka, C.L.; Benjamin, E.J.; Berra, K.; Bushnell, C.; Dolor, R.J.; Ganiats, T.G.; Gomes, A.S.; Gornik, H.L.; Gracia, C.; Gulati, M.; Haan, C.K.; Judelson, D.R.; Keenan, N.; Kelepouris, E.; Michos, E.D.; Newby, L.K.; Oparil, S.; Ouyang, P.; Oz, M.C.; Petitti, D.; Pinn, V.W.; Redberg, R.F.; Scott, R.; Sherif, K.; Smith, S.C., Jr; Sopko, G.; Steinhorn, R.H.; Stone, N.J.; Taubert, K.A.; Todd, B.A.; Urbina, E.; Wenger, N.K. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation, 2007, 115(11), 1481-1501.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.181546] [PMID: 17309915]

Miller, M.; Bachorik, P.S.; McCrindle, B.W.; Kwiterovich, P.O., Jr Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study. Am. J. Med., 1993, 94(1), 7-12.
[http://dx.doi.org/10.1016/0002-9343(93)90113-4] [PMID: 8420303]

Grundy, S.M. Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Arch. Intern. Med., 2001, 161(11), 1379-1380.
[http://dx.doi.org/10.1001/archinte.161.11.1379] [PMID: 11386886]

Blaha, M.J.; Blumenthal, R.S.; Brinton, E.A.; Jacobson, T.A. National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol reporting in lipid management. J. Clin. Lipidol., 2008, 2(4), 267-273.
[http://dx.doi.org/10.1016/j.jacl.2008.06.013] [PMID: 21291742]

Remick, J.; Weintraub, H.; Setton, R.; Offenbacher, J.; Fisher, E.; Schwartzbard, A. Fibrate therapy: an update. Cardiol. Rev., 2008, 16(3), 129-141.
[http://dx.doi.org/10.1097/CRD.0b013e31816b43d3] [PMID: 18414184]

Elisaf, M. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin., 2002, 18(5), 269-276.
[http://dx.doi.org/10.1185/030079902125000516] [PMID: 12240789]

Tavori, H.; Fan, D.; Blakemore, J.L.; Yancey, P.G.; Ding, L.; Linton, M.F.; Fazio, S. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation, 2013, 127(24), 2403-2413.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.001592] [PMID: 23690465]

Ooi, T.C.; Krysa, J.A.; Chaker, S.; Abujrad, H.; Mayne, J.; Henry, K.; Cousins, M.; Raymond, A.; Favreau, C.; Taljaard, M.; Chrétien, M.; Mbikay, M.; Proctor, S.D.; Vine, D.F. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. J. Clin. Endocrinol. Metab., 2017, 102(9), 3452-3460.
[http://dx.doi.org/10.1210/jc.2017-00684] [PMID: 28673045]

Reyes-Soffer, G.; Pavlyha, M.; Ngai, C.; Thomas, T.; Holleran, S.; Ramakrishnan, R.; Karmally, W.; Nandakumar, R.; Fontanez, N.; Obunike, J.; Marcovina, S.M.; Lichtenstein, A.H.; Matthan, N.R.; Matta, J.; Maroccia, M.; Becue, F.; Poitiers, F.; Swanson, B.; Cowan, L.; Sasiela, W.J.; Surks, H.K.; Ginsberg, H.N. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation, 2017, 135(4), 352-362.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025253] [PMID: 27986651]

Watts, G.F.; Chan, D.C.; Somaratne, R.; Wasserman, S.M.; Scott, R.; Marcovina, S.M.; Barrett, P.H.R. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur. Heart J., 2018, 39(27), 2577-2585.
[http://dx.doi.org/10.1093/eurheartj/ehy122] [PMID: 29566128]

Skulas-Ray, A.C.; Wilson, P.W.F.; Harris, W.S.; Brinton, E.A.; Kris-Etherton, P.M.; Richter, C.K.; Jacobson, T.A.; Engler, M.B.; Miller, M.; Robinson, J.G.; Blum, C.B.; Rodriguez-Leyva, D.; de Ferranti, S.D.; Welty, F.K. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation, 2019, 140(12), e673-e691.
[http://dx.doi.org/10.1161/CIR.0000000000000709] [PMID: 31422671]

Vecka, M.; Dušejovská, M.; Stankova, B.; Zeman, M.; Vavrova, L.; Kodydkova, J.; Slaby, A.; Zak, A. N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Neuroendocrinol. Lett., 2012, 33(Suppl. 2), 87-92.
[PMID: 23183517]

Kastelein, J.J.P.; Maki, K.C.; Susekov, A.; Ezhov, M.; Nordestgaard, B.G.; Machielse, B.N.; Kling, D.; Davidson, M.H. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J. Clin. Lipidol., 2014, 8(1), 94-106.
[http://dx.doi.org/10.1016/j.jacl.2013.10.003] [PMID: 24528690]

Nicholls, S.J.; Lincoff, A.M.; Bash, D.; Ballantyne, C.M.; Barter, P.J.; Davidson, M.H.; Kastelein, J.J.P.; Koenig, W.; McGuire, D.K.; Mozaffarian, D.; Pedersen, T.R.; Ridker, P.M.; Ray, K.; Karlson, B.W.; Lundström, T.; Wolski, K.; Nissen, S.E. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin. Cardiol., 2018, 41(10), 1281-1288.
[http://dx.doi.org/10.1002/clc.23055] [PMID: 30125052]

Ooi, E.M.M.; Watts, G.F.; Ng, T.W.K.; Barrett, P.H.R. Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients, 2015, 7(6), 4416-4425.
[http://dx.doi.org/10.3390/nu7064416] [PMID: 26043038]

Desmarchelier, C.; Borel, P.; Lairon, D.; Maraninchi, M.; Valéro, R. Effect of Nutrient and Micronutrient Intake on Chylomicron Production and Postprandial Lipemia. Nutrients, 2019, 11(6), 1299.
[http://dx.doi.org/10.3390/nu11061299] [PMID: 31181761]

Rizos, E.; Markozannes, G.; Tsapas, A.; Ntzani, E. Omega-3 Supplementation And Cardiovascular Disease: Meta-Analysis With Trial Sequential Analysis. Atherosclerosis, 2019, 287e284
[http://dx.doi.org/10.1016/j.atherosclerosis.2019.06.880]

Brasky, T.M.; Darke, A.K.; Song, X.; Tangen, C.M.; Goodman, P.J.; Thompson, I.M.; Meyskens, F.L., Jr; Goodman, G.E.; Minasian, L.M.; Parnes, H.L.; Klein, E.A.; Kristal, A.R. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J. Natl. Cancer Inst., 2013, 105(15), 1132-1141.
[http://dx.doi.org/10.1093/jnci/djt174] [PMID: 23843441]

Abdelhamid, A.S.; Brown, T.J.; Brainard, J.S.; Biswas, P.; Thorpe, G.C.; Moore, H.J.; Deane, K.H.; AlAbdulghafoor, F.K.; Summerbell, C.D.; Worthington, H.V.; Song, F.; Hooper, L. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst. Rev., 2018, 7(7)CD003177
[PMID: 30019766]

Kamanna, V.S.; Kashyap, M.L. Mechanism of action of niacin. Am. J. Cardiol., 2008, 101(8A), 20B-26B.
[http://dx.doi.org/10.1016/j.amjcard.2008.02.029] [PMID: 18375237]

Keenan, M. J. The Role of Niacin in the Management of Dyslipidemia.Dyslipidemia; McFarlane, S.I., Ed.; IntechOpen, 2019.
[http://dx.doi.org/10.5772/intechopen.81725]

Goldberg, R.B.; Bittner, V.A.; Dunbar, R.L.; Fleg, J.L.; Grunberger, G.; Guyton, J.R.; Leiter, L.A.; McBride, R.; Robinson, J.G.; Simmons, D.L.; Wysham, C.; Xu, P.; Boden, W.E. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. Am. J. Med., 2016, 129(7), 753.e13-753.e22.
[http://dx.doi.org/10.1016/j.amjmed.2016.02.039] [PMID: 27036394]

Li, C.; Zhang, W.; Zhou, F.; Chen, C.; Zhou, L.; Li, Y.; Liu, L.; Pei, F.; Luo, H.; Hu, Z.; Cai, J.; Zeng, C. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. PLoS One, 2013, 8(10)e77049
[http://dx.doi.org/10.1371/journal.pone.0077049] [PMID: 24204732]

Ference, B.A.; Kastelein, J.J.P.; Ginsberg, H.N.; Chapman, M.J.; Nicholls, S.J.; Ray, K.K.; Packard, C.J.; Laufs, U.; Brook, R.D.; Oliver-Williams, C.; Butterworth, A.S.; Danesh, J.; Smith, G.D.; Catapano, A.L.; Sabatine, M.S. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA, 2017, 318(10), 947-956.
[http://dx.doi.org/10.1001/jama.2017.11467] [PMID: 28846118]

Bowman, L.; Hopewell, J.C.; Chen, F.; Wallendszus, K.; Stevens, W.; Collins, R.; Wiviott, S.D.; Cannon, C.P.; Braunwald, E.; Sammons, E.; Landray, M.J. HPS3/TIMI55–REVEAL Collaborative Group. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N. Engl. J. Med., 2017, 377(13), 1217-1227.
[http://dx.doi.org/10.1056/NEJMoa1706444] [PMID: 28847206]

Armitage, J.; Holmes, M.V.; Preiss, D. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week. J. Am. Coll. Cardiol., 2019, 73(4), 477-487.
[http://dx.doi.org/10.1016/j.jacc.2018.10.072] [PMID: 30704580]

Majmudar, M.D.; Yoo, J.; Keliher, E.J.; Truelove, J.J.; Iwamoto, Y.; Sena, B.; Dutta, P.; Borodovsky, A.; Fitzgerald, K.; Di Carli, M.F.; Libby, P.; Anderson, D.G.; Swirski, F.K.; Weissleder, R.; Nahrendorf, M. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ. Res., 2013, 112(5), 755-761.
[http://dx.doi.org/10.1161/CIRCRESAHA.111.300576] [PMID: 23300273]

Palekar, R.U.; Jallouk, A.P.; Lanza, G.M.; Pan, H.; Wickline, S.A. Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Nanomedicine (Lond.), 2015, 10(11), 1817-1832.
[http://dx.doi.org/10.2217/nnm.15.26] [PMID: 26080701]

Bejarano, J.; Navarro-Marquez, M.; Morales-Zavala, F.; Morales, J.O.; Garcia-Carvajal, I.; Araya-Fuentes, E.; Flores, Y.; Verdejo, H.E.; Castro, P.F.; Lavandero, S.; Kogan, M.J. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics, 2018, 8(17), 4710-4732.
[http://dx.doi.org/10.7150/thno.26284] [PMID: 30279733]

Alkhalil, M.; Biasiolli, L.; Chai, J.T.; Galassi, F.; Li, L.; Darby, C.; Halliday, A.; Hands, L.; Magee, T.; Perkins, J.; Sideso, E.; Jezzard, P.; Robson, M.D.; Handa, A.; Choudhury, R.P. Quantification of carotid plaque lipid content with magnetic resonance T2 mapping in patients undergoing carotid endarterectomy. PLoS One, 2017, 12(7)e0181668
[http://dx.doi.org/10.1371/journal.pone.0181668] [PMID: 28746385]

Yang, S.; Moon, Y-A. Current Drugs, Targets, and Drug Delivery Systems for the Treatment of Dyslipidemia. J. Pharm. Investig., 2018, 48(3), 233-241.
[http://dx.doi.org/10.1007/s40005-017-0353-5]

Kosmas, C.E.; Muñoz Estrella, A.; Sourlas, A.; Silverio, D.; Hilario, E.; Montan, P.D.; Guzman, E. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. Diseases, 2018, 6(3), 63.
[http://dx.doi.org/10.3390/diseases6030063] [PMID: 30011788]

Ray, K.K.; Landmesser, U.; Leiter, L.A.; Kallend, D.; Dufour, R.; Karakas, M.; Hall, T.; Troquay, R.P.T.; Turner, T.; Visseren, F.L.J.; Wijngaard, P.; Wright, R.S.; Kastelein, J.J.P. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N. Engl. J. Med., 2017, 376(15), 1430-1440.
[http://dx.doi.org/10.1056/NEJMoa1615758] [PMID: 28306389]

Iacobucci, G. Inclisiran: UK to roll out new cholesterol lowering drug from next year. BMJ, 2020, 368, m139.
[http://dx.doi.org/10.1136/bmj.m139] [PMID: 31932283]

Bandyopadhyay, D.; Hajra, A.; Ashish, K.; Qureshi, A.; Ball, S. New hope for hyperlipidemia management: Inclisiran. J. Cardiol., 2018, 71(5), 523-524.
[http://dx.doi.org/10.1016/j.jjcc.2017.10.017] [PMID: 29174841]

Fitzgerald, K.; White, S.; Borodovsky, A.; Bettencourt, B.R.; Strahs, A.; Clausen, V.; Wijngaard, P.; Horton, J.D.; Taubel, J.; Brooks, A.; Fernando, C.; Kauffman, R.S.; Kallend, D.; Vaishnaw, A.; Simon, A. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N. Engl. J. Med., 2017, 376(1), 41-51.
[http://dx.doi.org/10.1056/NEJMoa1609243] [PMID: 27959715]

NCT03399370. Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol (ORION-10), Available at: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01521995/full

NCT03400800. Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11), Available at: https://clinicaltrials.gov/ct2/show/NCT03400800

Simental-Mendía, L.E.; Guerrero-Romero, F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial. Nutrition, 2019, 58, 7-10.
[http://dx.doi.org/10.1016/j.nut.2018.06.015] [PMID: 30278430]

Gomes, A.P.O.; Ferreira, M.A.; Camargo, J.M.; Araújo, M.O.; Mortoza, A.S.; Mota, J.F.; Coelho, A.S.G.; Capitani, C.D.; Coltro, W.K.T.; Botelho, P.B. Organic beet leaves and stalk juice attenuates HDL-C reduction induced by high-fat meal in dyslipidemic patients: A pilot randomized controlled trial. Nutrition, 2019, 65, 68-73.
[http://dx.doi.org/10.1016/j.nut.2019.03.004] [PMID: 31029925]

Barcelos de Castro, A.P.R.; Antunes de Moraes, A.E.; Simabuco, F.M.; Massa, G.O.; Corona, L.P.; Bezerra, R.M.N. Beetroot Leaves (Beta Vulgaris L.) Assist in Cholesterol Reduction in Dyslipidemic Obese Adults. Free Radic. Biol. Med., 2018, 120((Suppl. 1)), S123.
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.04.406]

Caro-Gómez, E.; Sierra, J.A.; Escobar, J.S.; Álvarez-Quintero, R.; Naranjo, M.; Medina, S.; Velásquez-Mejía, E.P.; Tabares-Guevara, J.H.; Jaramillo, J.C.; León-Varela, Y.M.; Muñoz-Durango, K.; Ramírez-Pineda, J.R. Green Coffee Extract Improves Cardiometabolic Parameters and Modulates Gut Microbiota in High-Fat-Diet-Fed ApoE^-/- Mice. Nutrients, 2019, 11(3), 497.
[http://dx.doi.org/10.3390/nu11030497] [PMID: 30818779]

Salamat, S.; Sharif, S.S.; Nazary-Vanani, A.; Kord-Varkaneh, H.; Clark, C.C.T.; Mohammadshahi, M. The Effect of Green Coffee Extract Supplementation on Serum Oxidized LDL Cholesterol and Total Antioxidant Capacity in Patients with Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial. Eur. J. Integr. Med., 2019, 28, 109-113.
[http://dx.doi.org/10.1016/j.eujim.2019.05.001]

Askarpour, M.; Hadi, A.; Symonds, M.E.; Miraghajani, M.; Sadeghi, O.; Sheikhi, A.; Ghaedi, E. Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis., 2019, 29(11), 1151-1167.
[http://dx.doi.org/10.1016/j.numecd.2019.07.012] [PMID: 31561944]

Youssef, D.A.; El-Fayoumi, H.M.; Mahmoud, M.F. Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-γ receptors. Chem. Biol. Interact., 2019, 297, 16-24.
[http://dx.doi.org/10.1016/j.cbi.2018.10.010] [PMID: 30343038]

Mendoza-Sánchez, M.; Pérez-Ramírez, I.F.; Wall-Medrano, A.; Martinez-Gonzalez, A.I.; Gallegos-Corona, M.A.; Reynoso-Camacho, R. Chemically Induced Common Bean (Phaseolus Vulgaris L.) Sprouts Ameliorate Dyslipidemia by Lipid Intestinal Absorption Inhibition. J. Funct. Foods, 2019, 52, 54-62.
[http://dx.doi.org/10.1016/j.jff.2018.10.032]

Bertuccioli, A.; Moricoli, S.; Amatori, S.; Rocchi, M.B.L.; Vici, G.; Sisti, D. Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules-A Meta-Analysis. J. Med. Food, 2020, 23(2), 101-113.
[http://dx.doi.org/10.1089/jmf.2019.0088] [PMID: 31441678]

Hu, M.; Zeng, W.; Tomlinson, B. Evaluation of a Crataegus -Based Multiherb Formula for Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Evidence-Based Complement. Altern. Med., 2014, 2014, 365742-365742.
[http://dx.doi.org/10.1155/2014/365742]

Romo-araiza, A.; Ríos-hoyo, A.; Ibarra, A.; Hernández-ortega, M.; Meneses-mayo, M. Effect of a Formulation with Nopal (Opuntia Ficus Indica), Amaranth (Amaranthus Cruentus) and Mushroom (Pleurotus Ostreatus) in a Murine Model of Diet-Induced Cardiometabolic Disruptions. Insights Nutr. Metab., 2018, 2(1), 1-13.

Ishibashi, S.; Yamashita, S.; Arai, H.; Araki, E.; Yokote, K.; Suganami, H.; Fruchart, J-C.; Kodama, T. K-877-04 Study Group. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016, 249, 36-43.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.02.029] [PMID: 27062408]

Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.; Itakura, H.; Kita, T.; Kitabatake, A.; Nakaya, N.; Sakata, T.; Shimada, K.; Shirato, K. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007, 369(9567), 1090-1098.
[http://dx.doi.org/10.1016/S0140-6736(07)60527-3] [PMID: 17398308]

NCT01492361. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major cardiovascular event,

Bhatt, D.L.; Steg, P.G.; Miller, M.; Brinton, E.A.; Jacobson, T.A.; Ketchum, S.B.; Doyle, R.T., Jr; Juliano, R.A.; Jiao, L.; Granowitz, C.; Tardif, J-C.; Ballantyne, C.M. REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N. Engl. J. Med., 2019, 380(1), 11-22.
[http://dx.doi.org/10.1056/NEJMoa1812792] [PMID: 30415628]

Bosch, J.; Gerstein, H.C.; Dagenais, G.R.; Díaz, R.; Dyal, L.; Jung, H.; Maggiono, A.P.; Probstfield, J.; Ramachandran, A.; Riddle, M.C.; Rydén, L.E.; Yusuf, S. ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med., 2012, 367(4), 309-318.
[http://dx.doi.org/10.1056/NEJMoa1203859] [PMID: 22686415]

NCT00069784. The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN) Available at: https://www.clinicaltrials.gov/ct2/show/NCT00069784

Leslie, M.A.; Cohen, D.J.A.; Liddle, D.M.; Robinson, L.E.; Ma, D.W.L. A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis., 2015, 14(1), 53.
[http://dx.doi.org/10.1186/s12944-015-0049-7] [PMID: 26048287]

Saraswathi, V.; Heineman, R.; Alnouti, Y.; Shivaswamy, V.; Desouza, C.V. A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation. J. Diabetes Complications, 2020, 34(2)107494
[http://dx.doi.org/10.1016/j.jdiacomp.2019.107494] [PMID: 31787562]

Schettler, V.J.J.; Neumann, C.L.; Peter, C.; Zimmermann, T.; Julius, U.; Roeseler, E.; Heigl, F.; Grützmacher, P.; Blume, H.; Vogt, A. Scientific Board of GLAR for the German Apheresis Working Group. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on. Clin. Res. Cardiol. Suppl., 2017, 12(S1)(Suppl. 1), 44-49.
[http://dx.doi.org/10.1007/s11789-017-0089-9] [PMID: 28233268]

Viney, N.J.; van Capelleveen, J.C.; Geary, R.S.; Xia, S.; Tami, J.A.; Yu, R.Z.; Marcovina, S.M.; Hughes, S.G.; Graham, M.J.; Crooke, R.M.; Crooke, S.T.; Witztum, J.L.; Stroes, E.S.; Tsimikas, S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, 2016, 388(10057), 2239-2253.
[http://dx.doi.org/10.1016/S0140-6736(16)31009-1] [PMID: 27665230]

NCT03070782. Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease Available at: https://www.clinicaltrials.gov/ct2/show/NCT03070782

Vogt, A. Lipoprotein(a)-antisense therapy. Clin. Res. Cardiol. Suppl., 2019, 14(S1)(Suppl. 1), 51-56.
[http://dx.doi.org/10.1007/s11789-019-00096-2] [PMID: 30859384]

Ray, K.K.; Bays, H.E.; Catapano, A.L.; Lalwani, N.D.; Bloedon, L.T.; Sterling, L.R.; Robinson, P.L.; Ballantyne, C.M. CLEAR Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N. Engl. J. Med., 2019, 380(11), 1022-1032.
[http://dx.doi.org/10.1056/NEJMoa1803917] [PMID: 30865796]

Goldberg, A.C.; Leiter, L.A.; Stroes, E.S.G.; Baum, S.J.; Hanselman, J.C.; Bloedon, L.T.; Lalwani, N.D.; Patel, P.M.; Zhao, X.; Duell, P.B. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA, 2019, 322(18), 1780-1788.
[http://dx.doi.org/10.1001/jama.2019.16585] [PMID: 31714986]

Siafaka, P.I.; Üstündağ Okur, N.; Karavas, E.; Bikiaris, D.N. Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses. Int. J. Mol. Sci., 2016, 17(9), 1440.
[http://dx.doi.org/10.3390/ijms17091440] [PMID: 27589733]

Sarangi, B.; Mishra, K.; Mohanta, G.P.; Manna, P.K. In Vitroin Vivo Correlation (IVIVC) of Solid Lipid Nanoparticles Loaded with Poorly Water-Soluble Drug Lovastatin. Eur. Polym. J., 2020, 122(1), 109366.
[http://dx.doi.org/10.1016/j.eurpolymj.2019.109366]

Siafaka, P.I.; Barmbalexis, P.; Bikiaris, D.N. Novel electrospun nanofibrous matrices prepared from poly(lactic acid)/poly(butylene adipate) blends for controlled release formulations of an anti-rheumatoid agent. Eur. J. Pharm. Sci., 2016, 88, 12-25.
[http://dx.doi.org/10.1016/j.ejps.2016.03.021] [PMID: 27039136]

Siafaka, P.I.; Üstündağ Okur, N.; Mone, M.; Giannakopoulou, S.; Er, S.; Pavlidou, E.; Karavas, E.; Bikiaris, D.N. Two Different Approaches for Oral Administration of Voriconazole Loaded Formulations: Electrospun Fibers versus β-Cyclodextrin Complexes. Int. J. Mol. Sci., 2016, 17(3), 282.
[http://dx.doi.org/10.3390/ijms17030282] [PMID: 26927072]

Kajdič, S.; Zupančič, Š.; Roškar, R.; Kocbek, P. The potential of nanofibers to increase solubility and dissolution rate of the poorly soluble and chemically unstable drug lovastatin. Int. J. Pharm., 2020, 573118809
[http://dx.doi.org/10.1016/j.ijpharm.2019.118809] [PMID: 31678525]

Al-Shdefat, R.; Anwer, M.K.; Fayed, M.H.; Alsulays, B.B.; Tawfeek, H.M.; Abdel-Rahman, R.F.; Soliman, G.A. Preparation and Evaluation of Spray Dried Rosuvastatin Calcium-PVP Microparticles for the Improvement of Serum Lipid Profile. J. Drug Deliv. Sci. Technol., 2020, 55101342
[http://dx.doi.org/10.1016/j.jddst.2019.101342]

Rizvi, S.Z.H.; Shah, F.A.; Khan, N.; Muhammad, I.; Ali, K.H.; Ansari, M.M.; Din, F.U.; Qureshi, O.S.; Kim, K.W.; Choe, Y.H.; Kim, J.K.; Zeb, A. Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model. Int. J. Pharm., 2019, 560, 136-143.
[http://dx.doi.org/10.1016/j.ijpharm.2019.02.002] [PMID: 30753932]

Sayadi, K.; Rahdar, A.; Hajinezhad, M.R.; Nikazar, S.; Susan, M.A.B.H. Atorvastatin-Loaded SBA-16 Nanostructures: Synthesis, Physical Characterization, and Biochemical Alterations in Hyperlipidemic Rats. J. Mol. Struct., 2020, 1202127296
[http://dx.doi.org/10.1016/j.molstruc.2019.127296]

Shaker, M.A.; Elbadawy, H.M.; Shaker, M.A. Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic® solid dispersions. Int. J. Pharm., 2020, 574118891
[http://dx.doi.org/10.1016/j.ijpharm.2019.118891] [PMID: 31786357]

Zhang, Y.; Zhang, X.; Zeng, C.; Li, B.; Zhang, C.; Li, W.; Hou, X.; Dong, Y. Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR). Bioorg. Med. Chem., 2019, 27(11), 2187-2191.
[http://dx.doi.org/10.1016/j.bmc.2019.04.019] [PMID: 31005367]

Katsiki, N.; Theocharidou, E.; Karagiannis, A.; Athyros, V.G.; Mikhailidis, D.P. Ezetimibe therapy for dyslipidemia: an update. Curr. Pharm. Des., 2013, 19(17), 3107-3114.
[http://dx.doi.org/10.2174/13816128113199990314] [PMID: 23317398]

Alshamsan, A.; Kazi, M.; Badran, M.M.; Alanazi, F.K. Role of Alternative Lipid Excipients in the Design of Self-Nanoemulsifying Formulations for Fenofibrate: Characterization, in vitro Dispersion, Digestion and ex vivo Gut Permeation Studies. Front. Pharmacol., 2018, 9, 1219.
[http://dx.doi.org/10.3389/fphar.2018.01219] [PMID: 30455642]

Kevadiya, B.D.; Chen, L.; Zhang, L.; Thomas, M.B.; Davé, R.N. Fenofibrate Nanocrystal Composite Microparticles for Intestine-Specific Oral Drug Delivery System. Pharmaceuticals (Basel), 2019, 12(3), 109.
[http://dx.doi.org/10.3390/ph12030109] [PMID: 31315263]

Shelake, S. Patil, S. V; Sangave, P. Formulation and Evaluation of Fenofibrate-Loaded Nanoparticles by Precipitation Method. Indian J. Pharm. Sci., 2018, 80(3), 420-427.
[http://dx.doi.org/10.4172/pharmaceutical-sciences.1000374]

Yuan, C.; Zhang, X.; Long, X.; Jin, J.; Jin, R. Effect of β-sitosterol self-microemulsion and β-sitosterol ester with linoleic acid on lipid-lowering in hyperlipidemic mice. Lipids Health Dis., 2019, 18(1), 157.
[http://dx.doi.org/10.1186/s12944-019-1096-2] [PMID: 31351498]